Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory
International Journal of Molecular Sciences · 05.03.2023 · 24 (5) · 4997
DOI: 10.3390/ijms24054997 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.03.2023. Verfasst von Valentina Artusa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry and Immunology, IRCCS MultiMedica, 20138 Milan, Italy. Hauptthemen laut MEDLINE: Biological Products, Neoplasms, Microbiota. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research, Fondazione Cariplo, Ricerca Corrente Rete Cardiologica IRCCS 2022.
Abstract (Originalsprache)
Cancer stem cells (CSCs) have drawn much attention as important tumour-initiating cells that may also be crucial for recurrence after chemotherapy. Although the activity of CSCs in various forms of cancer is complex and yet to be fully elucidated, opportunities for therapies targeting CSCs exist. CSCs are molecularly distinct from bulk tumour cells, so they can be targeted by exploiting their signature molecular pathways. Inhibiting stemness has the potential to reduce the risk posed by CSCs by limiting or eliminating their capacity for tumorigenesis, proliferation, metastasis, and recurrence. Here, we briefly described the role of CSCs in tumour biology, the mechanisms involved in CSC therapy resistance, and the role of the gut microbiota in cancer development and treatment, to then review and discuss the current advances in the discovery of microbiota-derived natural compounds targeting CSCs. Collectively, our overview suggests that dietary intervention, toward the production of those identified microbial metabolites capable of suppressing CSC properties, is a promising approach to support standard chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry and Immunology, IRCCS MultiMedica, 20138 Milan, Italy.
- Immunology and General Pathology Laboratory, Department of Biotechnology and Life Sciences, University of Insubria, 21100 Varese, Italy.
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy.
ORCID-Profile: Valentina Artusa, Luana Calabrone, Lorenzo Mortara, Francesco Peri, Antonino Bruno
Förderung
- Italian Association for Cancer Research
- Fondazione Cariplo
- Ricerca Corrente Rete Cardiologica IRCCS 2022
- Ricerca Corrente, IRCCS MultiMedica
- FAR 2023
- FAR 2022
- Cariplo Foundation
Zitieren
APA
Artusa, V., Calabrone, L., Mortara, L., Peri, F., & Bruno, A. (2023). Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. International Journal of Molecular Sciences, 24(5), 4997. https://doi.org/10.3390/ijms24054997
Vancouver
Artusa V, Calabrone L, Mortara L, Peri F, Bruno A. Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. International Journal of Molecular Sciences. 2023;24(5):4997. doi:10.3390/ijms24054997
BibTeX
@article{Artusa2023,
author = {Artusa, Valentina and Calabrone, Luana and Mortara, Lorenzo and Peri, Francesco and Bruno, Antonino},
title = {Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {5},
pages = {4997},
doi = {10.3390/ijms24054997}
}
EUVIMED